Morgan Stanley Harmony Biosciences Holdings, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Morgan Stanley holds 758,863 shares of HRMY stock, worth $19.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

758,863

Previous 656,104 15.66%

Holding current value

$19.7 Million

Previous $21.8 Million 10.12%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$27.94 - $35.91 $2.87 Million - $3.69 Million	102,759 Added 15.66%	758,863 $24 Million
Q1 2025 May 15, 2025	SELL	$32.18 - $40.46 $4.85 Million - $6.1 Million	-150,779 Reduced 18.69%	656,104 $21.8 Million
Q4 2024 Feb 14, 2025	SELL	$31.86 - $41.49 $1.4 Million - $1.82 Million	-43,795 Reduced 5.15%	806,883 $27.8 Million
Q3 2024 May 14, 2025	BUY	$30.0 - $39.95 $437,010 - $581,951	14,567 Added 1.74%	850,678 $34 Million
Q3 2024 Nov 14, 2024	BUY	$30.0 - $39.95 $437,010 - $581,951	14,567 Added 1.74%	850,678 $34 Million
Q2 2024 May 14, 2025	BUY	$28.81 - $33.01 $842,058 - $964,816	29,228 Added 3.62%	836,111 $25.2 Million
Q2 2024 Oct 17, 2024	SELL	$28.81 - $33.01 $1.42 Million - $1.63 Million	-49,234 Reduced 5.56%	836,111 $25.2 Million
Q2 2024 Aug 14, 2024	SELL	$28.81 - $33.01 $1.42 Million - $1.63 Million	-49,234 Reduced 5.56%	836,111 $25.2 Million
Q1 2024 Oct 17, 2024	BUY	$29.93 - $35.06 $1.47 Million - $1.73 Million	49,234 Added 5.89%	885,345 $29.7 Million
Q1 2024 Aug 16, 2024	SELL	$29.93 - $35.06 $6.01 Million - $7.04 Million	-200,870 Reduced 18.49%	885,345 $29.7 Million
Q1 2024 May 15, 2024	SELL	$29.93 - $35.06 $6.01 Million - $7.04 Million	-200,870 Reduced 18.49%	885,345 $29.7 Million
Q4 2023 Aug 16, 2024	BUY	$19.2 - $33.78 $4.8 Million - $8.45 Million	250,104 Added 29.91%	1,086,215 $35.1 Million
Q4 2023 Feb 13, 2024	BUY	$19.2 - $33.78 $6.35 Million - $11.2 Million	330,770 Added 43.78%	1,086,215 $35.1 Million
Q3 2023 Nov 15, 2023	BUY	$31.89 - $39.03 $810,675 - $992,181	25,421 Added 3.48%	755,445 $24.8 Million
Q2 2023 Aug 14, 2023	BUY	$30.5 - $37.4 $5.12 Million - $6.28 Million	167,952 Added 29.88%	730,024 $25.7 Million
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $5.11 Million - $8.94 Million	165,756 Added 41.82%	562,072 $18.4 Million
Q4 2022 Feb 14, 2023	BUY	$45.4 - $60.91 $3.34 Million - $4.48 Million	73,534 Added 22.78%	396,316 $21.8 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $4.6 Million - $6.06 Million	109,305 Added 51.2%	322,782 $14.3 Million
Q2 2022 Oct 27, 2022	BUY	$33.54 - $52.15 $1.74 Million - $2.71 Million	51,903 Added 32.12%	213,477 $10.4 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $1.74 Million - $2.71 Million	51,903 Added 32.12%	213,477 $10.4 Million
Q1 2022 Oct 27, 2022	SELL	$33.14 - $51.13 $1.72 Million - $2.65 Million	-51,903 Reduced 24.31%	161,574 $7.86 Million
Q1 2022 May 13, 2022	SELL	$33.14 - $51.13 $315,923 - $487,422	-9,533 Reduced 5.57%	161,574 $7.86 Million
Q4 2021 Feb 14, 2022	BUY	$34.09 - $43.91 $4.32 Million - $5.56 Million	126,623 Added 284.65%	171,107 $7.3 Million
Q3 2021 Nov 15, 2021	BUY	$25.68 - $38.61 $1.14 Million - $1.72 Million	44,484 New	44,484 $1.71 Million

Others Institutions Holding HRMY

# of Institutions

290

Shares Held

46.3M

Call Options Held

316K

Put Options Held

69.9K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $1.54B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account